ProShare Advisors
PCVX icon

ProShare Advisors’s Vaxcyte PCVX Stock Holding History

ProShare Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.42M Sell
24,449
-2,276
-9% -$124K ﹤0.01% 728
2025
Q4 		$1.23M Buy
26,725
+2,524
+10% +$113K ﹤0.01% 771
2025
Q3 		$872K Sell
24,201
-6,408
-21% -$212K ﹤0.01% 855
2025
Q2 		$995K Sell
30,609
-2,083
-6% -$68.3K ﹤0.01% 821
2025
Q1 		$1.23M Sell
32,692
-8,183
-20% -$654K ﹤0.01% 757
2024
Q4 		$3.35M Buy
40,875
+11,729
+40% +$1.16M 0.01% 591
2024
Q3 		$3.33M Buy
29,146
+8,212
+39% +$740K 0.01% 596
2024
Q2 		$1.58M Sell
20,934
-5,733
-21% -$390K ﹤0.01% 695
2024
Q1 		$1.82M Buy
26,667
+5,060
+23% +$350K ﹤0.01% 678
2023
Q4 		$1.36M Buy
21,607
+3,285
+18% +$171K ﹤0.01% 699
2023
Q3 		$934K Buy
18,322
+302
+2% +$14.9K ﹤0.01% 736
2023
Q2 		$900K Buy
18,020
+4,030
+29% +$191K ﹤0.01% 750
2023
Q1 		$524K Sell
13,990
-1,770
-11% -$75.1K ﹤0.01% 893
2022
Q4 		$756K Buy
15,760
+4,833
+44% +$190K ﹤0.01% 803
2022
Q3 		$262K Buy
10,927
+464
+4% +$11.8K ﹤0.01% 1229
2022
Q2 		$228K Sell
10,463
-3,364
-24% -$77.8K ﹤0.01% 1391
2022
Q1 		$334K Sell
13,827
-2,428
-15% -$53K ﹤0.01% 1550
2021
Q4 		$387K Sell
16,255
-72
-0.4% -$1.68K ﹤0.01% 1629
2021
Q3 		$414K Sell
16,327
-3,217
-16% -$78K ﹤0.01% 1324
2021
Q2 		$440K Buy
19,544
+4,750
+32% +$97.2K ﹤0.01% 1617
2021
Q1 		$292K Buy
14,794
+2,897
+24% +$72.9K ﹤0.01% 1822
2020
Q4 		$316K Buy
+11,897
New +$442K ﹤0.01% 1579

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's PCVX Position: Q1 2026 in Review

ProShare Advisors reduced its Vaxcyte (PCVX) stake by 8.5% in Q1 2026, selling an estimated $124K and leaving 24,449 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #728.

ProShare Advisors first reported a position in PCVX in Q4 2020 and has held it in 22 quarters since. The position peaked at $3.35M in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • ProShare Advisors held 24,449 shares of Vaxcyte worth $1.42M as of Q1 2026.
  • ProShare Advisors sold 2,276 Vaxcyte shares in Q1 2026, an estimated $124K.
  • Vaxcyte made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #728 holding.
  • ProShare Advisors first reported a position in Vaxcyte in Q4 2020 and has held it in 22 quarters since.
  • ProShare Advisors's Vaxcyte position peaked at $3.35M in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.